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Asthma research has focused primarily on allergic pathways on the basis that the majority of asthma is asso-
ciated with atopy, the recruitment of the Th2-type T cell, the cytokines, and the chemokines that are released
on exposure to allergens, and the IgE pathway. However, despite considerable investment by industry,
targeting these pathways has not resulted in new treatments being developed beyond blockade of cysteinyl
leukotrienes and IgE and improvements in inhaled corticosteroids and b2-adrenoceptor bronchodilators.
Increasingly, it is recognized that asthma is a heterogeneous disorder, and while important, allergen sensi-
tization is only one component of the disease, with many other environmental and genetic factors playing
a role. In addition, these factors act locally on a susceptible airway epithelium that is both structurally and
functionally deficient. It may be worthwhile to focus on increasing the resilience of the airways to environ-
mental insults in addition to improving strategies that modify adaptive immunity or suppress inflammation.Current Shortfalls in Understanding
Asthma Pathogenesis
Asthma is a common disease that afflicts
all ages and can vary greatly in severity. It
is primarily an inflammatory disorder of
the conducting airways upon which is
superimposed both an increase in smooth
muscle and a change in its responsive-
ness to stimulation that manifests clini-
cally as variable airflow obstruction. The
disease is also characterized by varying
degrees of airway-wall remodeling linked
to more fixed airflow obstruction and
a gradual decline in lung function over
time. Another degree of complexity is
the wide number of environmental factors
associated with the inception of asthma,
its persistence, and its acute deterioration
(exacerbations) that include exposure to
inhaled allergens, air pollutants, certain
drugs, occupational chemicals, and envi-
ronmental tobacco smoke. Most fre-
quently, asthma begins in early childhood,
although the factors that contribute to its
origin are still not known. Its course can
vary widely over time, with up to half the
children entering into remission during
the adolescent and young adult years
but with a propensity to return later in life
again through mechanisms that are poor-
ly understood. One reason why we know
so little about those factors that con-
tribute to its origin and the different phe-
notypes that ensue is because, until
relatively recently, asthma has not been
studied across the life course. Even in
late-onset asthma in adults, we know little
about those factors that initiate the362 Immunity 31, September 18, 2009 ª200disease other than to the form associated
with exposure to occupational chemicals.
In the case of nonallergic asthma, where
there is a conspicuous absence of atopy,
almost nothing is known about its origins
or how and why it can persist.
From a therapeutic standpoint, asthma
is mostly managed with a combination of
short- and long-acting bronchodilators
and inhaled corticosteroids that target
the inflammatory and smooth muscle re-
sponses. Although effective in the major-
ity of patients, this approach to manage-
ment falls a long way short of being
ideal, as reflected by low patient adher-
ence to treatment, dependency on the
use of inhaled drugs (sometimes for life),
and the remaining unmet clinical need,
especially from exacerbations, at the
severe end of the disease spectrum
(approximately 10%). Patient-based sur-
veys of asthma conducted in many coun-
tries all reveal similar findings of a persist-
ing disease burden and impaired quality
of life (Holgate et al., 2008). This does
not mean that progress has not been
made over the last two decades. Indeed,
the introduction of management guide-
lines initially focused on a stepwise
approach to drug use but more recently
focused on attaining complete control
has reducedmortality and hospital admis-
sions where such guidelines are adhered
to (Haahtela et al., 2006). However, the
question that needs to be asked is
whether this dependence on suppressive
drugs is an end in itself or whether we
should be aspiring to higher gains for9 Elsevier Inc.asthma sufferers. As the editor of the
Lancet highlighted in a recent issue of
this journal dedicated to asthma, ‘‘Prog-
ress in understanding asthma and its
underlying mechanisms is slow; treat-
ment can be difficult and response unpre-
dictable; and prevention and cure are still
a pipedream’’ (The Lancet, 2008).
So where do we go from here? Over the
last 50 years, there have only been two
therapeutic targets introduced that have
translated to patient benefit: the dis-
covery of cysteinyl leukotrienes (CysLTs)
and their receptors and immunoglobulin
(Ig) E leading to leukotriene antagonists
and synthesis inhibitors and the IgE
blocking monoclonal antibody, omalizu-
mab, both targets originally identified
many years ago. Part of the problem in
identifying novel ways to treat asthma
upstream of the inflammatory and remod-
eling responses is the notion that these
aspects of asthma and disordered
smooth muscle function are driven pri-
marily by exposure to allergen, sensitiza-
tion with production of IgE, and the
subsequent recruitment of T lymphocytes
differentiated to secrete an array of cyto-
kines encoded in the IL4 gene cluster on
chromosome 5q. Undoubtedly, allergen-
driven inflammation plays a role in the
clinical manifestations of most asthma,
with recruitment of mast cells, basophils,
macrophages, and eosinophils to the
airways where they secrete an array of
mediators, including CysLTs, that interact
with the formed elements of the airways
resulting in airflow obstruction. However,
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satisfactorily is whether these T helper 2
(Th2) responses are primary, or whether
they are secondary to other events that
render the airways susceptible to asthma.
One might go one step further and ask
whether adaptive immunologic events
are at the center of asthma pathogenesis
or whether the disease originates within
the lung itself, leading to recruitment of
immune-effector mechanisms. This is
important not least because most of the
‘‘novel’’ therapeutic targets that have
been identified from animal models have
emerged from using short- or long-term
variants of antigen (usually ovalbumen)
challenge following peritoneal sensitiza-
tion in conjunction with adjuvant, such
as Freunds or alum (Wenzel and Holgate,
2006). Reliance on such models, espe-
cially in rodents, emerged from the more
traditional use of animals in pharmacology
that helped in the discovery and improve-
ment of bronchodilators, cromone-like
anti-allergic drugs (e.g., cromolyn so-
dium, nedocromil sodium, lodoxamide),
anti-histamines, corticosteroids, cystLT
modifiers, and anti-IgE.
Considering Asthma
as a Th2 Disease
In their review, Barrett and Austen (2009)
point out some of the anomalies of con-
sidering asthma purely as a Th2 disease.
A range of new inflammatory cells and
cytokines may be involved, including
invariant NKT cells, Th17 cells and their
associated cytokines IL-17 A and IL-17 F,
IL-25, IL-33, and thymic stromal lympho-
poietin (TSLP), the latter three being
derived from the epithelium and all
capable of driving either an eosinophilic,
neutrophilic, or combined inflammatory
response. However, in looking at the
supportive evidence for any one of these,
the evidence has largely accrued through
manipulating the gene encoding the
cytokine or its receptor in mice coupled
with a range of antigen-challenged
rodent models. For each pathway, there
is evidence of expression in asthmatic
airways but difficulty in selecting any one
as taking primacy. In some respects, this
has been a problem with research that
has underpinned the components of the
Th2 pathway that, despite predictions
from in vitro and animal models, have so
far proved somewhat disappointing as
asthma targets. In rodents and, in somecases in nonhuman primates, blockade
of IL-4, IL-5, IL-9, eotaxin, and IL-13 or
attempts to manipulate the T cell re-
sponse in favor of Th1 cells all produce
remarkable inhibitory responses on anti-
gen sensitization and challenge models,
although with no or less effect on an
ongoing established Th2 response asso-
ciated with remodeling changes (Holgate
and Polosa, 2008).
Despite considerable initial optimism,
blocking antibodies or soluble receptors
that target Th2 cytokines or their recep-
tors have been disappointing. In the
case of IL-5, the blocking monoclonal
antibody mepolizumab was shown to be
highly effective in almost abolishing circu-
lating and sputum eosinophils in asthma
but had no discernable effect on clinical
outcome measures. Of importance, in
two subsequent small studies of mepoli-
zumab highlighted by Barrett and Austen
(2009) conducted in patients with persis-
tent eosinophilia despite oral corticoste-
roids, revealed efficacy mostly against
exacerbation (but not BHR). Thus, the
concept that within the population of
asthmatics there are subpopulations of
IL-5 mAb responders raises the important
issue of different disease phenotypes
(Wenzel, 2009). Thus, although at one
time considered as a single-disease
entity, asthma subphenotypes are now
recognized with differing pathology, clin-
ical expression, responses to treatment,
and long-term outcomes. The initial prom-
ising results with the anti-IgE mAb in
severe asthma with associated allergy
has also been revisited recently with the
recognition of responders and nonre-
sponders requiring up to 12 weeks treat-
ment before a decision regarding future
therapy can be made on combined clin-
ical grounds because no biomarker of
efficacy has so far been found (Holgate
et al., 2009).
The latest Th2 cytokine target to come
under scrutiny is IL-13 because of its Th-2
type inflammatory profile, its capacity to
promote mucus formation and secretion,
and its effect in promoting remodeling in
rodent models. Abrogation of IL-13 in
these models has a dramatic effect at
reducing all aspects of the asthma-like
features following single or repeated an-
tigen challenge. This cytokine has, there-
fore, become the most popular recent
target against which to direct a new
asthma therapy. As a consequence, thereImmunity 31, Sare at least 12 biologics that are in clinical
development designed to block IL-13 or
its receptors. Despite this enthusiastic
response by the pharmaceutical and
biotechnology industries, the evidence
linking asthma to IL-13 is limited to
in vitro studies on human cells, some
genetic association studies, and a few
observational studies in which IL-13 has
been measured in induced sputum and
airway biopsies. Notably, there are no
functional studies using airway explants
from different types of asthma to show
that blockade of IL-13 has any useful
effect in this complex disease. Most
recently, there have been two allergen
challenge studies and one phase 2 clinical
trial inmoderate-severe asthma that show
efficacy that is limited and unfortunately
no better than cromolyn sodium that has
recently been removed from the WHO
list of approved drugs for asthma on
account of limited efficacy. With the Am-
gen IL-4R-IL-13Ra1 blocking monoclonal
antibody (mAb), there appears to be a
small subgroup with the severest disease
where there was a suggestion of efficacy.
As further phase 2 clinical studies are
completed, it will be of great interest to
see whether the animal model predictions
for IL-13 translate into patient benefit or
whether this is going to be yet another
target that emphasizes our incomplete
understanding of disease pathogenesis
in humans.
Attacking the Inflammatory
Effecter Cells
Rather than targeting individual cytokines,
chemokines, and autacoid mediators, an
alternative strategy has been to target
the effecter cells themselves to inhibit
their recruitment or their activation. In
many ways, this is an attractive approach
because it makes no assumptions as to
why the cells are there in the first place.
Mast Cells
The mast cell has long been known to be
a sentinel cell of the allergen-induced
early- and late-phase airway response
through the release of granule-associated
and newly formed mediators and cyto-
kines. Indeed, the rationale behind the
introduction of inhaled cromolyn sodium
in asthma therapy was through inhibiting
mast cells, but its mechanism of action
has never been clearly established (Hol-
gate, 1989). While these drugs were used
for many years in asthma prophylaxis,eptember 18, 2009 ª2009 Elsevier Inc. 363
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out of favor on account of their limited effi-
cacy across the asthma spectrum (van
der Wouden et al., 2008). However, its
efficacy and safety in a subset of allergic
and exercise-induced asthma is unques-
tionable; the problem was how to identify
those that best respond—another
example of stratified medicine (Stevens
et al., 2007).
The last decade has witnessed an
explosion in knowledge of mast cell
ontogeny, subtypes, and activation-
secretion coupling involving both cell-
bound IgE and other stimuli. Despite
this, there have been no additional
asthma treatments to emerge that block
mast cell mediator secretion, although
there have been many attempts. Mucosal
mast cells are largely T cell dependent
and are sensitive to being inhibited by
cromolyns (MCT) but only account for a
proportion of the mast cells that con-
tribute to asthma. Of particular relevance
here is the dominance of the connective
tissue mast cell (MCTC) prominent in the
airway’s smooth muscle and more pe-
ripheral airways, and which is involved in
more severe disease (Bradding, 2009).
The finding of a high population of MCTC
in asthmatic airway smooth muscle, as
well as a unique set of signalingmolecules
involved in muscle and mast cell commu-
nication, raises the important issue of
whether these unique cells are primarily
involved in programming the asthmatic
airways smooth muscle and vice versa.
Mast cells are an important source of
Th2 cytokines and tumor necrosis factor
alpha (TNFa). In severe corticosteroid
refractory asthmaassociatedwith amixed
neutrophilic and eosinophilic inflamma-
tory response, TNFa expression is greatly
enhanced both at mRNA and protein
levels. However, despite initial promising
results of small trials blocking TNFa with
etanercept (soluble TNF receptor fusion
protein) (Howarth et al., 2005) or a mAb
(infliximab) (Erin et al., 2006), two large
randomized control trials (RCTs) using
etanercept or golimumab, a fully human
monoclonal antibody against TNFa, failed
to confirm this, though in the latter trial,
there may be a subgroup with upper
airways disease and bronchodilator
reversibility that may respond (Wenzel
et al., 2009). As with selective IL-5 and
IL-13 blockade, variation in response to
inhibiting TNFa might be a further364 Immunity 31, September 18, 2009 ª200example of subphenotypes (or endo-
types) of severe asthma that respond to
different interventions (Anderson, 2008).
Eosinophils
The eosinophil is the other effecter cell
associated with asthma and certainly in
animal models of antigen-driven airway
inflammation and BHR; it has been caus-
ally linked, although this has depended on
the mouse strain and stimulus. In asthma,
the evidence is correlative. Previous refer-
ence has been made to the negative
results of IL-5 blockade apart from the
few patients with highly eosinophilic
asthma in the face of high-dose cortico-
steroids, but this still does not definitively
answer the question about the role of
eosinophils per se in this disease. The
nearest we are likely to get to this is the
upcoming trial of an antibody-dependent
cell cytotoxic defucosylated IgG1 mono-
clonal antibody (MEDI-563) directed to
all cells expressing the IL-5ra. Engi-
neering of mAbs by removing fucose resi-
dues from the Fc fragment leads to greatly
enhanced antigen-dependent cellular
cytotoxicity (ADCC) activity as compared
to a highly fucosylated conventional anti-
body (Yamane-Ohnuki et al., 2004). Data
from a completed Phase 1 study of
MEDI-563 have demonstrated the anti-
body is well tolerated with substantial
and prolonged depletion of blood eosino-
phils, thereby supporting its continued
development.
T Lymphocytes
A similar approach is being taken to
manipulate the Th2 T cell population.
Th-2-type T cells are greatly enriched
with CCR4, the principle chemokine
receptor responsible for allergen-induced
migration of these cells into asthmatic
airways. AMG 761 (previously KW-0761)
is a humanized IgG1monoclonal antibody
targeted to CCR4-positive T cells and
leads to depletion of CCR4-positive
T cells as a therapy for asthma. This anti-
body has already shown efficacy in re-
lapsed patients with adult T cell leukemia-
lymphoma and cutaneous T cell
lymphoma, including mycosis fungoides
and Se´zary syndrome (Yano et al., 2007).
Another T cell subtype that has at-
tracted much recent interest in asthma is
the regulatory T cell (Treg) (Akdis and
Akdis, 2009). In their review of a potential
role for regulatory T cells, Lloyd and
Hawrylowicz (2009) emphasize the impor-
tance of these cells in mediating allergen-9 Elsevier Inc.specific tolerance through the secretion of
IL-10, a known suppressive cytokine.
Treg cells have also been strongly impli-
cated in the efficacy of both allergen
subcutaneous and sublingual immuno-
therapy, including peptide immunother-
apy. As a broad approach to treating
asthma, it seems that clinical efficacy
may be limited to mild-moderate allergic
asthma, where one specific allergen is a
major contributor, e.g., cat Fel d1.
Another exciting development made by
Hawrylowicz is the capacity of vitamin
D3 to reverse corticosteroid refractori-
ness of circulating mononuclear cells
from patients with difficult-to-treat asth-
ma through induction of IL-10. Clinical
trials are now in progress. TGFb is also
an immunosuppressive cytokine that
promotes the differentiation of an ‘‘adap-
tive’’ subset of Tregs (Curotto de Lafaille
and Lafaille, 2009), but as discussed by
Lloyd andHawrylowicz, this is also a profi-
brotic cytokine, so manipulation to
enhance its production could enhance
remodeling and promote epithelial-
mesenchymal transition (Boxall et al.,
2006).
Invariant natural killer T (iNKT) cells
have aroused interest as potential media-
tors of asthmatic inflammation. These
specialized T cells recognize endogenous
and exogenous glycolipid antigens in the
context of the CD1d receptor and secrete
cytokines (especially interferons and
CXCR3 chemokines) that amplify both
innate and adaptive immunity. Although
outside the Th2 hypothesis of asthma, in
mice, these cells have been incriminated
in neutrophlic inflammation. The initial
high-profile interest in iNKT cells has
largely come from mouse models and
initial reports of their high numbers in
asthmatic lavage fluid (Akbari et al.,
2006). Application of more stringent
analytical techniques for their detection
by flow cytometry using CD1d tetramers
loaded with alpha-galactosylceramide
and antibodies specific to the invariant
natural killer T cell receptor in samples of
lavage fluid, induced sputum, and bron-
chial-biopsy specimens has revealed
that <2%of T cells belong to this subtype,
compared to initial claims of upwards of
60% (Vijayanand et al., 2007). Selective
antagonists and blocking monoclonal
antibodies for CD1d are being developed
that will enable functional studies in
humans.
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in the Airway Structural Cells?
The up-to-date review by Lambrecht and
Hammad (2009) focuses attention on the
dendritic cell (DC) as a target for inter-
vening to control asthma. These function
in antigen recognition and can be pro-
grammed through innate mechanisms to
shape the subsequent adaptive immune
response. In addition to covering the
different subsets and ontogeny of DCs,
this review focuses attention on the role
of the airway epithelium to instruct DCs
along their differentiation pathway. It is
surprising that it has taken so long to
place the airway epithelium in the context
of asthmatic inflammation and remodel-
ing because in all subtypes of asthma,
irrespective of age, evidence of epithelial
activation and damage is one of the
most prominent features. In 2000, this
led us to suggest that asthma is a disorder
of the epithelium, with connections both
to the origin and sustenance of airway
inflammation, as well as being the
principle driver of remodeling (epithelial-
mesenchymal trophic unit, EMTU) (Hol-
gate et al., 2000). DCs extend their pro-
cesses up between adjacent columnar
epithelial cells and make intimate contact
with the expression of tight junction pro-
teins. As pointed out by Lambrecht and
Hammad, crosstalk between these airway
elements is likely to be fundamental to the
origins and emergence of asthma sub-
phenotypes across the life course. One
mediator that has aroused interest in this
respect is thymic stromal lymphopoetin
(TSLP), whose release from the airway
epithelium upon activation of selective
toll-like receptors (TLRs) 2, 4, 8, and 9
lead to upregulation of OX40L on DCs
and their increased capacity to drive a
Th2 response (Holgate, 2007a). The cru-
cial question is the nature of this epithe-
lial-DC interaction. A clue has come from
understanding the pathogenesis of exac-
erbations.
It is now clear that most exacerbations
of asthma, both in adults and children,
occur in relation to respiratory virus expo-
sure following upper respiratory tract
infections, although exposure to seasonal
allergens and air pollutants are also
causes (Sears, 2008). Rhinoviruses (RVs)
seem to account for the majority of the
causative organisms, especially with the
recent identification of the RV C clade
(Miller et al., 2009). In 2005, we reportedthat asthmatic airway epithelial cells are
deficient in their capacity to generate
IFNb in response to RV 16 infection
in vitro (Wark et al., 2005). This was asso-
ciated with an inability of the cells to limit
viral replication by entering into apo-
ptosis, with the consequence that the
replicating virus caused cytopathic cell
death with extensive virus shedding.
Subsequently, a similar defect in IFNb
production has been shown with the
minor subtype RV1B (Wark et al., 2009).
Addition of exogenous IFNb restored the
asthmatic cells’ ability to eliminate the
virus. Human recombinant IFNb by inhala-
tion is being developed as a treatment to
prevent asthma exacerbations in severe
disease.
Early life exposure to respiratory viruses
is now considered to be a major predis-
posing factor in the induction of asthma.
A recent important discovery is that
repeated infections with rhinovirus (RV)
during the first 3 years of life increased
the risk of developing asthma by age 6
years 26-fold compared to 3-fold for
allergen sensitization (Jackson et al.,
2008). The key role of early life virus infec-
tion extends into adult asthma in the
European Community Respiratory Health
Survey (Dharmage et al., 2009). In a U.S.
95,000 infant cohort study, the timing of
birth in relationship to the winter virus
season conferred a 30% increased risk
of developing asthma by 6 years of age
(Wu et al., 2008), while in a Perth cohort,
respiratory virus infection (RV = 70% and
RSV = 16%) positively interacted with
atopy to promote later asthma at 5 years
of age (Kusel et al., 2007). Importantly,
the target for viruses and environmental
stimuli such as ETS and other pollutants
is the airway epithelium. Understanding
why the airway epithelium of these chil-
dren is so susceptible to these stimuli
and how it affects allergic sensitization
provides a potential new route to prevent
asthma.
As discussed by Lambrecht and Ham-
mad, airway DCs play a critical role in initi-
ating and regulating early inflammatory
events. In the first year of life, infants do
not typically exhibit airway DCs in the
absence of inflammation, but severe re-
spiratory infection is a powerful stimulus
for their appearance (Tschernig et al.,
2001). Thus, it is possible that respiratory
virus infection of the asthmatic epithelium
causes airway DC maturation with a pref-Immunity 31, Serential bias toward a Th2 response to the
penetrating allergen. This proposal is sup-
ported by showing that, in response to
TLR3 agonists, bronchial epithelial cells
from asthmatic subjects make less IFN-b
and more TSLP than those from normal
donors. Other epithelial defects that are
intrinsic to the asthmatic epithelium are
a reduction in antioxidant capability and
impaired formation of tight junctions
leading to reduced barrier function.
Taken together, a structurally and func-
tionally defective airway epithelium un-
derlies abnormal responses to respiratory
viruses and other components of the
inhaled environment (Figure 1). This would
promote a microenvironment that facili-
tates allergic sensitization, supports dif-
ferent types of inflammation, and predis-
poses the airways to development of
asthma during childhood.
Airway Remodeling in Asthma
Bronchial biopsies from very young chil-
dren with early life virus-associated
wheezing reveal little abnormal pathol-
ogy, but by the age of 3 years, epithelial
injury and thickening of the lamina reticu-
laris is evident, either in the absence or
presence of Th2 type inflammation. While
thickening of the lamina reticularis is diag-
nostic of asthma in children and adults,
there is doubt over its importance to
airway remodeling because it does not
relate to asthma duration, although may
increase with severity. Based upon its
presence in asthma and following lung
transplantation, deposition of new matrix
in the lamina reticularis is indicative of
chronic epithelial injury (Holgate, 2007b).
The proliferation of airway smooth mus-
cle, epithelial mucous metaplasia, in-
crease in neural and vascular networks,
and the deposition of matrix throughout
the airway wall translates into airway
hyper-responsiveness, fixed airflow ob-
struction, and a progress decline in lung
function over time that characterizes
chronic persistent asthma. In adult and
childhood asthma, epithelial overexpres-
sion of epidermal growth factor receptor,
reduced markers of cell proliferation
(Ki67, PCNA), and increased nuclear
translocation of the cell-cycle inhibitor
P21waf are consistent with impaired
epithelial repair responses. Most recently,
airway epithelial cells cultured from atopic
asthmatic, when compared to those from
atopic or nonatopic normal children, showeptember 18, 2009 ª2009 Elsevier Inc. 365
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Figure 1. Schematic Representation of Factors that Interact in the Initiation and Persistence
of Asthma
The developing fetal lung expresses genes that predispose the airways to both structural and immunolog-
ical changes that favor the development of asthma in early childhood. An interaction between vulnerable
airways and multiple inhaled environmental insults, including allergens, environmental tobacco smoke,
viruses, pollutants, and other chemicals, translate into airway inflammation and tissue remodeling. This
involves increased susceptibility of the epithelium to injury, impaired repair, and activation of mesen-
chymal cells, leading to persistent inflammation, airway hyper-reactivity, and remodeling. These interac-
tions are also influenced by gender and age as well as physical interactions generated by repeated
bronchoconstriction. Environmental factors acting at different stages throughout the life course probably
act together in generating the different asthma subtypes, susceptibility to treatment, and natural history.
The hyper-reactive asthmatic airway manifests in variable airflow obstruction in response to a range of
different insults such as allergens, exercise, cold air, and irritants.greatly impaired wound repair responses
following injury (Stevens et al., 2008). An
additional important stimulus for profibro-
genic growth factor release is epithelial
distortion consequent upon repeated
cycles of bronchoconstriction. The con-
sequences of these events are enga-
gemement of the trophic activity of the
EMTU to promote airway remodeling
and increased airway smooth muscle
(Figure 1).
An Approach to Prevention
and Treatment
The important role of the physical and
functional barrier functions in atopic
dermatitis (eczema), food allergy, and rhi-366 Immunity 31, September 18, 2009 ª200nosinusitis is now being realized with
defects in filaggrin, S100, and claudin
proteins, respectively, indicating that this
might be a generic feature for acquiring
mucosal allergy. Based on this primary
role of the airway epithelium in the group
of disorders’ causation and persistence,
an approach to preventing and treating
asthmacouldbe to increase the resistance
of the epithelium to the inhaled environ-
ment, perhaps in addition to suppressing
the immune and inflammatory responses
once they have become established.
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